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Abstract 
 Background: Depression has been linked with obesity and with inflammation, and those 
conditions may be especially important for treatment-resistant forms of depression. It has been 
hypothesized that inflammation is a mediator between obesity and depression. Adiponectin is a 
peptide hormone secreted from adipose tissue. It is associated with peripheral inflammation and 
is found at lower concentrations in obese individuals. Furthermore, adiponectin is shown to 
cause hippocampal growth and antidepressant effects which are also observed in 
electroconvulsive therapy (ECT). We investigated the relationship between treatment response, 
obesity, and plasma adiponectin levels in a cohort of patients receiving ECT for refractory 
depression. 
Methods: Blood was collected from 77 patients with severe, refractory depression (major 
depressive disorder or bipolar disorder) at baseline and at two time points during a course of 
ECT. Patients had no known acute inflammatory conditions. Adiponectin levels were measured 
in plasma using enzyme-linked immunosorbent assay. Body mass index (BMI) was used as a 
measure of obesity. ECT was delivered as clinically indicated, and treatment response was 
evaluated at the end of ECT treatment course. Depression ratings were obtained during 
naturalistic follow-up at 6 and 12 months. 
Results: We found an association between BMI and poor treatment response 6 months 
post treatment (r = .338, p = 0.015, two-sided, Pearson Correlation). Adiponectin Assays are still 
being conducted but preliminary results indicate that it may hold promise as a predictor of 
response to ECT. 
Conclusions: Obesity is associated with poorer clinical response to ECT in this sample. 
Adiponectin can be reliably measured in plasma and may be a mediator of the relationship 
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between obesity and depression. To further investigate, we are conducting more adiponectin 
assays on our entire cohort and expanding our sample size.  
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Treatment-resistant Depression, Obesity, and Adiponectin 
Patients with severe major depression for whom pharmacologic interventions have been 
unsuccessful may pursue Electroconvulsive Therapy (ECT) to alleviate their symptoms. ECT is 
an invasive procedure that involves electrically inducing a seizure which produces a therapeutic 
effect. The mechanisms responsible for the therapeutic effect are not well understood despite the 
70+ year history of ECT (Rudorfer, Henry, & Sackeim, 1865). For many of the patients who 
undergo ECT, the treatment provides a much desired relief from their depressive symptoms. 
Unfortunately, approximately one-third of the patients who undergo ECT do not respond 
(Dierckx, Heijnen, van den Broek, & Birkenhäger, 2012; Gomez, 1975; Rudorfer et al., 1865).  
The causes of treatment resistance are unknown, so clinicians are unable to predict when 
a particular patient will respond favorably to the treatment.  Consequently, several hospital 
resources are invested in ECT for patients for whom the treatment is ineffective. ECT is an 
expensive and invasive treatment which involves risks associated with general anesthetics and 
may include temporary short term memory loss (Rudorfer et al., 1865).  In order to minimize the 
number of patients who undergo ECT and do not experience remission, it is imperative that a 
clinical tool is developed for predicting when patients will benefit from ECT. In this study, we 
investigated potential biomarkers that could predict response to ECT.  
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Obese patients have an increased risked for developing depression over healthy controls. 
The risk of an obese individual developing depression increases with metabolic risk factors such 
as high blood pressure and inflammation. A study of over 30,000 individuals reported that 
metabolically unhealthy obese patients (classified as being obese and having 2 or more metabolic 
risk factors) have 23% higher odds of developing depressive symptoms when compared to obese 
patients who have 1 or fewer metabolic risk factors. The study also reported that the chance of 
developing depressive symptoms increased linearly with additional metabolic risk factors  
(Jokela, Hamer, Singh-Manoux, Batty, & Kivimäki, 2014). 
These findings further support the notion that depression is associated with dysfunction 
of metabolic pathways such as inflammatory responders or metabolism regulation. Obese 
patients also have poorer treatment outcomes for psychiatric treatment and are more likely to be 
re-hospitalized within the first year of discharge from psychiatric treatment (Manu et al., 2014). 
Obese patients with mental illness, especially those with metabolic risk factors, are not receiving 
treatment which adequately addresses their psychiatric symptoms. We hypothesized that ECT 
may be less effective for these obese patients. 
Inflammation and obesity have been of interest as biomarkers for treatment response as 
they have been linked with depression. It is hypothesized that inflammation is a mediator 
between obesity and depression (Shelton & Miller, 2010). A chronic increase of inflammatory 
factors or decrease in anti-inflammatory factors is thought to have secondary effects on the brain 
(Miller, Maletic, & Raison, 2009; Shelton & Miller, 2010).  
 From animal models, we know that ECT increases hippocampal growth. It is thought that 
this neurogenesis is related to the therapeutic effect of the treatment (Evans et al., 2004; Madsen 
et al., 2000; Yau et al., 2014). Hippocampal neurogenesis with anti-depressant effects has been 
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related to adiponectin secretion. Specifically, animal models have indicated that exercise induced 
adiponectin secretion has led to neurogenesis in the hippocampal region and subsequently led to 
a decrease in depressive symptoms (see figure A1) (Yau et al., 2014).  
Adiponectin (see figure A2) is a polypeptide hormone with 244 amino acids. It helps 
regulate glucose, and fatty acid oxidation as well as participating in many other metabolic 
pathways (Diez & Iglesias, 2003). It is secreted from adipose tissue, yet it is inversely correlated 
with body fat percentage in adults which has perplexed scientists (Arita et al., 1999; Diez & 
Iglesias, 2003; M. Liu & Liu, 2012; Scherer, Williams, Fogliano, Baldini, & Lodish, 1995; 
Ukkola & Santaniemi, 2002). There is also a noted sex and age difference in adiponectin levels 
with adiponectin higher in females and with increasing age (Cnop et al., 2003).  
Two adiponectin receptors, ADIPOR1 and ADIPOR2 are expressed typically in skeletal 
muscle and liver respectively. However, both receptors have been found in brain tissue. 
ADIPOR1 is found in mood regulatory regions of the brain, specifically the hippocampus and is 
believed to be responsible for adiponectin activated neurogenesis and the subsequent 
antidepressant effects reported in animal models (Yamauchi et al., 2003; Yau et al., 2014).  
Adiponectin circulates in the bloodstream in three oligomer complexes (trimmers, 
hexamers, and high molecular weight oligomers (HMW)). The trimmeric (LMW) and hexameric 
(MMW) forms are found in the cerebral spinal fluid and are capable of passing through the blood 
brain barrier (Lam et al., 2009; Wang et al., 2005; Yau et al., 2014).  
Several studies have investigated the relationship of adiponectin and depression with the 
indication that adiponectin levels may be lower in depressed populations. Yet, these studies have 
several confounding factors, primarily heterogeneity in depressed patient samples (Carvalho et 
al., 2014; Lehto et al., 2010; Leo et al., 2006; Taylor & MacQueen, 2010). However, in 
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controlled animal experiments, adiponectin was significantly lower in depressed mice and the 
depressive symptoms could be ameliorated by intravenous adiponectin infusion (J. Liu et al., 
2012). Because adiponectin is founded at a lower concentration in obese patients, the lower 
levels of adiponectin may be part of the mechanism by which obese individuals, especially those 
with metabolic risk factors develop depression (Jokela et al., 2014; Yau et al., 2014).  
In the animal studies where it was found that adiponectin was lower in depressed mice, 
they reported no difference in the amount of adipose tissue from healthy controls (J. Liu et al., 
2012). If adiponectin levels are lowered in both depression and obesity, then obese patients with 
depression related to metabolic dysfunction may have very low adiponectin levels, lower than a 
non-obese depressed individual. This may in part explain the poor psychiatric treatment 
outcomes in obese individuals.  
 We hypothesize that adiponectin may be a mediator between obesity and depression, 
specifically related to the effects of adiponectin on hippocampal growth which is also associated 
with ECT. We expect that baseline adiponectin levels will be lower in our depressed patients and 
will be even lower in our obese depressed patients. It is unclear at which stage in the pathway 
ECT may compensate for adiponectin dysregulation but we suspect that pre-treatment 
adiponectin levels may help provide clinicians with a biomarker to help predict response to 
electroconvulsive therapy.  
Method 
The data reported here are from an ongoing prospective, longitudinal, observational study 
of patients undergoing ECT treatment for treatment resistant depression called Michigan 
Biomarkers for Refractory Depression (Bluebird). This project has collected clinical data and 
biospecimens from over 100 patients. Participants in the cohort are interviewed and clinically 
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assessed at baseline, during treatment, and post treatment. Blood samples are taken at baseline 
and two time points during their course of ECT (see figure A3). Whole blood was drawn in the 
morning in a fasted state (at least 7 hours) through an intravenous catheter or butterfly needle 
into 6-mL EDTA tubes (Lavender Top, Becton Dickinson Vacutainer® K2EDTA additive blood 
collection tube, part #367863) and transported to the processing lab at the Michigan Clinical 
Research Unit within 30 minutes.  Plasma was isolated by centrifugation for 10 minutes at 
2000G at 4°C.  Plasma from multiple tubes was pooled and aliquotted in 200 µL volumes into 2-
mL screw-cap cryovials and frozen at −80°C. The patient data is stored in a secure database and 
blood samples are stored at -80 degrees Celsius until needed for analysis. In order to be eligible 
for the study, patients had to meet the inclusion criteria seen in table A1. At the time of the 
current analysis, 77 participants have been included in our sample. 
Before undergoing ECT patients were assessed via a variety of psychiatric scales (see 
table A2). ECT was delivered as clinically indicated. Following the index course of ECT, 
patients were followed up with self-administered questionnaires at 6 and 12 month intervals post 
treatment. Few data are currently available at the 18 and 24 month follow-ups so those are not 
included in the current analyses.   
After treatment was completed, patient response to ECT was assessed by a clinician and 
patients were divided into three categories (non-responder, partial responder, and full responder) 
based on post treatment Hamilton Depression Scale (HAMD), Montgomery Asberg Depression 
Rating Scale (MADRS), and Clinical Global Impression scores.  Plasma concentrations of 
adiponectin were analyzed via enzyme-linked immunosorbent assay (ELISA) with HMW and 
total adiponectin ELISA kit (ALPCO, USA). Three different enzyme-treated fractions were 
assayed in order to measure LMW, MMW, HMW, and total adiponectin levels at all three time 
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points. Assays were conducted in accordance with manufacturer instructions. Absorbance values 
were converted to concentrations using a quadratic line of best fit to known concentration 
samples included in the kit. Body mass index (BMI) was used as a measure of obesity. 
Statistical Package for the Social Sciences (SPSS) (Version 22) was used to conduct 
analysis. We used one-way-ANOVA to test for differences between response groups. To test for 
differences between baseline and post treatment we used paired t-tests. Pearson correlations 
associations between continuous variables were also conducted to determine if any 
measurements were correlated with each other.  
Results 
Characteristics of the Sample 
We had 77 patients (46 female, 50.98 ± 15.36 years old; mean ± SD) who have 
completed an index course of ECT.  This cohort was notable for severe depression (baseline 
HAMD 17 item: 22 ± 4.62, mean ± SD) and for having 38 obese patients, defined as BMI over 
30 (see figure A4). The study also included 17 patients with bipolar disorder. The average 
duration of the current depressive episode was 18 ± 36 months (see table A3).  
Post treatment HAMD ratings and MADRS ratings were significantly lower than baseline 
(p < 0.05) supporting the therapeutic effect of ECT.  Patients received on average 10.16 ± 3.7, 
mean ± SD ECT treatments in their index course. Of the patients, 25 responded well to ECT, 22 
had a partial response, and 22 were non-responders to the therapy. 8 participants are still 
awaiting final clinical evaluation of treatment outcomes and were excluded from response 
analysis.   
Obesity and Depression Outcomes  
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We looked at the correlation of BMI and depression outcomes immediately after ECT 
and 6 and 12 months post treatment. HAMD 17 item ratings were analyzed for our immediate 
post treatment measures because they must be administered by a trained clinician. PHQ-9 scores 
were used as a measure of post treatment depression 6 and 12 months after treatment because it 
can be self-administered or assessed via a follow-up call.  
 BMI was found to be uncorrelated with post treatment HAMD 17 item scores (r = .123, p 
= .368, Pearson Correlation) (see table A9) and was not significantly different among BMI 
groups (t (54) = -.417, p = .75) (see table A7 and A11). Interestingly, baseline HAMD 17 item 
scores were significantly lower for obese patients (t (66) = 2.1, p < 0.04).  
However, PHQ-9 scores at 6 months were found to be correlated with BMI (r = .338, p = 
0.015 Person Correlation) (see table A9). PHQ-9 scores at 12 months were not correlated with 
BMI but the scores trended in the same direction as seen in 6 month PHQ-9 scores (r = .303, p = 
0.061). PHQ-9 scores were significantly higher for obese patients (BMI ≥ 30) 6 months after 
treatment (t (49) = -2.547, p = .014) and 12 months after treatment (t (37) = -2.028, p = .05) (see 
table A11 and figure A5).  QIDS scores were also higher 6 months post treatment for obese 
patients (t (37) = -2.387, p = 0.022). There was no significant difference of BMI among 
treatment response (see table A10).  
Adiponectin Assay Results 
 At the time of the current study, only 10 participants had adiponectin concentration data. 
The adiponectin assays yielded a coefficient of variation median of 1.36% with an inter quartile 
range of 1.99%. Total adiponectin concentrations averaged 7.25 ± 4.76, 6.87 ± 4.59, and 7.31 ± 
4.3 micrograms / milliliter, mean ± SD at baseline, time point 2, and time point 3 respectively 
(see table A5).  None of the three types of adiponectin measurements (total, LMW, MMW, or 
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HMW) varied significantly from baseline at time point 2 or 3 (see table A4 and 6). All 
adiponectin measurements were uncorrelated with BMI (table A8). However, the data is 
suggestive of an association between baseline total adiponectin levels and treatment response 
(see figures A6 and A7). 
Discussion 
We sought to identify potential biomarkers that could be used to predict treatment 
response to ECT. Given that obesity and inflammation are associated with depression and that 
obesity with metabolic risk factors increases risk for depression we hypothesized that markers of 
inflammation and obesity might help predict treatment response to ECT (Jokela et al., 2014; 
Shelton & Miller, 2010). Specifically we were interested in identifying how baseline adiponectin 
is related to treatment response in ECT. We looked at adiponectin as a potential biomarker 
because it is associated with increased hippocampal growth and antidepressant effects as is ECT 
(Evans et al., 2004; J. Liu et al., 2012; Yau et al., 2014). Furthermore, adiponectin levels are 
lower in obese patients and adiponectin is thought to be anti-inflammatory (Arita et al., 1999; 
Carvalho et al., 2014; Diez & Iglesias, 2003). We hypothesized that baseline adiponectin would 
be lower in patients who did not respond well to ECT and that those patients would also likely 
have a high BMI. We also were interested in determining if any other baseline factors related to 
treatment outcomes at 6, and 12 months post treatment.  
We found that Obesity predicted a higher PHQ-9 score 6 months after treatment. This 
indicates that obese patients are more likely to be depressed after treatment has passed which is 
consistent with the finding that depressed patients have poorer outcomes from psychiatric 
treatments  (Jokela et al., 2014).  However, the association of BMI with higher PHQ-9 scores 
was less significant at 12 months. This may be due to more non-obese patients experiencing 
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more depressive symptoms one year after treatment. The sample size at 12 months post treatment 
is also smaller so outliers might have had a greater effect on the analysis. 
Since we found that there was no difference between post treatment HAMD 17 item 
scores for obese patients, the increase in depressive symptoms 6 and 12 months post treatment 
for obese patients cannot be attributed to obese patients being more depressed in general.  
Furthermore, we found that obese patients actually had lower baseline HAMD 17 item scores 
prior to treatment.  
 There is indication from our preliminary data that lower baseline total adiponectin levels 
may predict response to ECT (see figure A6 and A7) which suggests that ECT may compensate 
for lower adiponectin levels. Specifically, LMW and MMW adiponectin as both oligomers are 
able to cross the blood brain barrier. Although our sample size of adiponectin assays is too small 
to make significant conclusions, the data is suggestive that the interaction of adiponectin and 
obesity may hold promise as a clinical tool for predicting response to ECT and should further be 
investigated. At the time of submission, we are in the process of completing adiponectin assays 
for the remaining participants.  
Since patients undergoing ECT have not responded well to traditional treatments, it is 
possible that ECT is compensating for a deficiency in the pathway of adiponectin induced 
hippocampal growth. If this were the case we would expect to find that baseline adiponectin 
levels may differ between patients who respond well to ECT versus non-responders. Although it 
would be difficult to identify the ineffective aspect of the adiponectin pathway as there may be 
several physiological issues that lead to the same symptoms of treatment resistant depression. It 
could be possible that the ADIPOR1 is ineffective or it could be that adiponectin transport across 
the blood brain barrier is impeded. There are several possible areas along the pathway that could 
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lead to the difficult to treat depressive symptoms. Poor response to ECT may also be due to 
depression caused by a different metabolic dysfunction. 
Limitation 
 While this study does analyze patients at baseline, during, and after treatment it is not 
without limitations. Primarily, our measure of adiponectin was only peripheral. We are not yet 
able to determine how adiponectin is interacting in the brain in humans. We did not control for 
medications after the course of ECT treatment which may have affected some patient’s outcomes 
during their follow-up surveys. Also, we were not able to control for other traumatic stressors or 
extraneous situations that could have altered a patient’s mental health at the time of their follow-
ups. Of course with the assays there is also the chance of human error.  
Future Directions 
We suggest that a more rigorous understanding of how adiponectin relates to depression, 
and especially its relation to ECT, is needed. Studies which investigate administration of ECT to 
adiponectin knock-out mice would be of particular interest. Such investigations could better our 
understanding of how the hippocampal neurogenesis observed in ECT and adiponectin secretions 
are related, if at all. Additionally, other compounds that relate to metabolism or inflammation 
such as C-reactive protein, cortisol, IL-6, Leptin, and IL-1ra  should be investigated as potential 
biomarkers for response to ECT as well (Carvalho et al., 2014).  
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Appendix 
Table A1 
Study Inclusion Criteria 
Inclusion criteria 
DSM-IV diagnosis of Major Depressive Disorder (MDD), Bipolar Disorder (BD), or Mood 
Disorder NOS where the major differential is MDD vs. BD 
Aged 18 years or older 
Current major depressive episode for at least 2 months 
Depression severity at least moderate (QIDS-SR ≥ 11 or MADRS ≥ 19) 
Lack of remission after at least 1 adequate medication trial during the current episode (for 
MDD, one antidepressant; for BD, lithium, anticonvulsant, antidepressant, or atypical 
antipsychotic)
a
 
OR intolerance to at least 3 medication trials during the current episode 
Capacity to give informed consent 
Exclusion criteria 
Medically or psychiatrically unstable during the week prior to study entry (urgent or inpatient 
treatment needed) 
Manic or mixed episode within the past 6 months 
Primary psychotic disorder (e.g., schizoaffective disorder) 
Mood or psychotic disorder due to general medical condition or substance use 
Dementia or delirium 
Axis II disorder as a current primary focus of treatment 
a 
An adequate medication trial will be defined by an "adequate" dose or serum level 
(according to ATHF criteria) for a minimum of 6 weeks 
* Component of the National Network of Depression Centers (NNDC) common assessment 
package 
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Table A2 
 
Patient Clinical Assessments  
 
 
 
 
Clinician-rated, baseline    
Montgomery Asberg Depression Rating Scale (MADRS)    
Hamilton Rating Scale for Depression (HamD29)    
Global Assessment of Functioning (GAF)    
Major Depression Checklist *    
Mania/Hypomania Checklist *    
Clinical Features of Depression Summary 
Montreal Cognitive Assessment (MoCA) 
   
    
Patient-rated, baseline and every 6 months    
Quick Inventory of Depressive Symptomatology (QIDS-SR16) *    
Patient Health Questionnaire (PHQ-9) *    
Altman Self-Rating Mania Scale (ASRM) *    
Work and Social Adjustment Scale (WSAS) *    
Survey of Recent Treatment    
    
Patient-rated, baseline only    
Inventory of Depressive Symptomatology (IDS-SR30 incl. 
QIDS-SR16) 
   
Generalized Anxiety Disorder scale (GAD-7) *    
Positive and Negative Affective Schedule (PANAS-X)    
Columbia Suicide Severity Rating Scale (C-SSRS) *    
Fagerstrom Test for Nicotine Dependence (FTND)    
    
Emotional Appetite Questionnaire (EMAQ)    
Self-administered Comorbidity Questionnaire (SCQ)    
Adverse Childhood Experience Questionnaire (ACE) *    
Life Events Occurrence Survey (LEOS)    
Antidepressant Treatment Response Questionnaire (ATRQ)    
The Personality Inventory for DSM-5 – Brief Form (PID-r-BF)    
    
* Component of the National Network of Depression Centers (NNDC) common assessment 
package 
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Table A3 
Demographic and Clinical Data  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n = 77 
Demographic    
Female, n, (%) 46 (59) 
age, yr, mean (SD) 50.98 (15.36) 
Body Mass Index, mean (SD) 30.48 (8.1) 
Number of Obese Patients (BMI >=30)  38 
Caucasian, n 72 
post or peri-menopausal, n 29 
education, yr, mean (SD) 15.71 (3.1) 
single / married / divorced / widowed, n 19 / 34 / 12 / 6 
Right Handed, n, (%) 69 (89) 
Clinical    
MDD recurrent / MDD single episode / Bipolar, n 50 / 10 / 17 
Current anxiety disorder, n  31 
melancholic features, n  62 
atypical features, n 4 
catatonic features, n 4 
psychotic features, n 8 
chronic episode, n 36 
episode duration , mo, median  (IQR) 18 (36) 
age of onset, yr, mean (SD) 21.52 (12.8) 
17-item hamilton depression rating, mean (SD) 22 (4.62) 
Montgomery-Asberg depression rating, mean (SD) 33.18 (6.33) 
Clinical global impression-severity, mean (SD) 5.64 (0.74) 
Global assessment of function mean (SD) 31.38 (10.192) 
Medication trials in current episode, mean (SD) 2.97 (2.16) 
Taking antidepressant medication, n  75 
Maudsley staging, mean (SD)  8.86 (1.95) 
Post-treatment ratings    
Number of adequate ECT treatments, mean (SD) 10.16 (3.37) 
17-item Hamilton depression rating, mean (SD) 10.50 (5.91)* 
Montgomery-Asberg depression rating, mean (SD) 13.95 (7.99)* 
Clinical global impression-severity, mean (SD) 3.07 (1.17) 
Montreal cognitive assessment, mean (SD)  26.58 (3.24) 
* significant difference from baseline p < 0.05   
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Table A4 
Correlation of Adiponectin Measurements by LMW, MMW, HMW, Total at Baseline and Two Time Points During Treatment  
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Table A5 
Descriptive Statistics for Adiponectin Measurements 
 
 
 
 
 
 
 
 
 
 
Note: measurements are in micrograms / milliliter. Negative measures are due to curve fitting 
extrapolation error. 
 
 
 
 
 
 
 
 
 
 
 
  N Minimum Maximum Mean 
Std. 
Deviation 
1Total 10 1.99 17.27 7.25 4.76 
1HMW 10 0.18 11.03 3.84 3.45 
1MMW 10 0.52 2.79 1.26 0.73 
1LMW 10 1.17 4.18 2.16 0.94 
2Total 10 1.50 15.19 6.87 4.59 
2HMW 10 0.15 9.71 3.75 3.22 
2MMW 10 0.37 5.34 1.63 1.70 
2LMW 10 -1.12 3.16 1.48 1.13 
3Total 10 1.17 14.30 7.31 4.30 
3HMW 10 0.16 9.74 4.09 3.08 
3MMW 10 -0.73 1.66 0.97 0.72 
3LMW 10 0.68 3.71 2.25 0.97 
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Table A6  
Paired T-Tests of Adiponectin Measurements at Time Points 2 and 3 Versus Baseline  
 
 
 
 
 
 
 
Paired Samples Test 
  
Paired Differences 
t df 
Sig. (2-
tailed) Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 
1 
1Total - 
2Total 
0.38 0.99 0.31 -0.33 1.09 1.222 9 .253 
Pair 
2 
1Total - 
3Total 
-0.06 1.93 0.61 -1.44 1.33 -.092 9 .929 
Pair 
3 
1HMW 
- 
2HMW 
0.08 0.69 0.22 -0.41 0.58 .369 9 .721 
Pair 
4 
1HMW 
- 
3HMW 
-0.25 1.16 0.37 -1.09 0.58 -.691 9 .507 
Pair 
5 
1MMW 
- 
2MMW 
-0.37 1.62 0.51 -1.54 0.79 -.730 9 .484 
Pair 
6 
1MMW 
- 
3MMW 
0.29 0.75 0.24 -0.25 0.83 1.214 9 .256 
Pair 
7 
1LMW 
- 
2LMW 
0.68 1.54 0.49 -0.43 1.78 1.388 9 .199 
Pair 
8 
1LMW 
- 
3LMW 
-0.09 1.03 0.32 -0.82 0.64 -.281 9 .785 
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Table A7  
ANOVA Tests Comparing HAMD-17 Item Scores by BMI Group 
 
Note. BMI groups: BMI < 25, 25 ≤ BMI < 30, and BMI ≥ 30 
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Table A8 
Correlation of BMI With Adiponectin Measurements at All Three Time Points  
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Table A9  
Correlations of BMI with Post Treatment HAMD 17 Item, MADRS, and PHQ-9 Scores at 6, 12 
and 18 Months  
 
 
 
 
 
 
 
 
 
 
 
 
Depression, Obesity, and Adiponectin   26 
 
Table A10 
ANOVA of BMI by Treatment Response  
ANOVA 
BMI 
 Sum of Squares df Mean Square F Sig. 
Between Groups 64.847 2 32.423 .448 .641 
Within Groups 4771.390 66 72.294   
Total 4836.237 68    
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Table A11 
Independent T-tests of Mean PHQ-9 and QIDS Score 6, and 12 Months Post Treatment as well as Mean Baseline PHQ-9 and Baseline 
and Post Treatment HAMD 17 Item Scores by Obesity Status (BMI ≥ 30) 
 
Note: PHQ-9 at 6 and 12 months, QIDS at 6 months, and HAMD 17 item scores at baseline are significant (p < 0.05) 
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Figure A1. Hypothesized pathway of adiponectin’s effect on hippocampal growth (Evans et al., 
2004; Madsen et al., 2000; Yau et al., 2014). 
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Figure A2. Crystal structure of a single-chain trimmer of human adiponectin globular domain 
PDB: 4DOU (Min et al., 2012; Shapiro & Scherer, 1998). 
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Figure A3. Study protocol timeline. 
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Figure A4.  Histogram of Obesity (BMI) 
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Figure A5. Box plot of PHQ 9 at 6 months post treatment divided by BMI and post treatment response.  
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Figure A6. Baseline Total Adiponectin levels plotted against patient response.  
 
 
 
 
 
 
 
 
Depression, Obesity, and Adiponectin   34 
 
 
Figure A7. Average total adiponectin at each time point by response group 
 
 
 
 
 
 
 
